

Abingdon Health appoints Biomedical Diagnostics as exclusive distributor for the Benelux region

27 August 2015

Abingdon Health Ltd, is pleased to announce that it has appointed Biomedical Diagnostics (“BMD”) as exclusive distributor for Belgium, The Netherlands and Luxembourg (“Benelux”) for the Seralite[®] – FLC rapid diagnostic test.

Seralite[®] – FLC is a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum as an aid to the diagnosis and management of multiple myeloma. The assay provides an accurate picture of disease status in 10 minutes. The simple to use, portable, rapid test allows the monitoring of patients in “real time” supporting faster decision making. By obtaining results rapidly, clinicians are able to better understand disease status and can make informed treatment decisions quickly and efficiently.

Biomedical Diagnostics (BMD) is a privately owned company which was founded in December 1986. Based in Antwerp, BMD is a distributor of reagents, instruments and technical support to clinics and laboratories in Belgium, The Netherlands and Luxembourg.

Commenting on the agreement, Chris Yates, said:

“We are delighted to announce BMD as our distributor. BMD are a well-established company with an experienced field based sales force in the Benelux region and we are confident they will be an excellent partner to support the roll-out of the Seralite[®] – FLC device across the region.”

Enquiries:

Abingdon Health Ltd
Chris Yates, CEO
Paul Duncan, Sales & Marketing Director

+44 121 414 5166

Notes to editors

About Abingdon Health – www.abingdonhealth.com

Abingdon Health Ltd is a UK based in vitro diagnostic group focused on developing a range of rapid testing products in the area of hematology oncology. The Company launched its first rapid testing product in March 2015, Seralite[®] – FLC, the world’s first rapid diagnostic device in multiple myeloma, and is in the process of launching a range of complementary rapid tests.

The Company’s core expertise lies in the development, manufacturing and commercialisation of rapid lateral flow immunoassay diagnostics and reader systems. To support its strategic plan Abingdon Health is currently developing a multiplexed immunoassay rapid testing system based on fully disposable medical diagnostics for the rapid testing market. This device uses organic light emitting diodes (OLEDs) and organic photodetectors (OPDs) for versatile and quantitative optical detection in a portable and disposable format.